Reneo Pharmaceuticals Stock Current Valuation
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
Valuation analysis of Reneo Pharmaceuticals helps investors to measure Reneo Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Reneo Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Reneo Pharmaceuticals is based on 3 months time horizon. Increasing Reneo Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Reneo stock is determined by what a typical buyer is willing to pay for full or partial control of Reneo Pharmaceuticals. Since Reneo Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Reneo Stock. However, Reneo Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.2 | Real 14.48 | Hype 18.65 |
The intrinsic value of Reneo Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Reneo Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Reneo Pharmaceuticals helps investors to forecast how Reneo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Reneo Pharmaceuticals more accurately as focusing exclusively on Reneo Pharmaceuticals' fundamentals will not take into account other important factors: Reneo Pharmaceuticals Company Current Valuation Analysis
Reneo Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Reneo Pharmaceuticals Current Valuation | (15.01 M) |
Most of Reneo Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reneo Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Reneo Pharmaceuticals has a Current Valuation of (15.01 Million). This is 100.1% lower than that of the Biotechnology sector and 100.32% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.09% higher than that of the company.
Reneo Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reneo Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reneo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reneo Pharmaceuticals by comparing valuation metrics of similar companies.Reneo Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Reneo Fundamentals
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (15.01 M) | |||
| Shares Outstanding | 3.34 M | |||
| Shares Owned By Insiders | 5.19 % | |||
| Shares Owned By Institutions | 87.75 % | |||
| Number Of Shares Shorted | 3.4 M | |||
| Price To Book | 0.79 X | |||
| EBITDA | (82.23 M) | |||
| Net Income | (77.39 M) | |||
| Cash And Equivalents | 126.85 M | |||
| Cash Per Share | 5.18 X | |||
| Total Debt | 973 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 15.84 X | |||
| Book Value Per Share | 2.30 X | |||
| Cash Flow From Operations | (63.68 M) | |||
| Short Ratio | 27.39 X | |||
| Earnings Per Share | (16.80) X | |||
| Target Price | 2.25 | |||
| Beta | 0.22 | |||
| Market Capitalization | 6.08 M | |||
| Total Asset | 107.44 M | |||
| Retained Earnings | (218.47 M) | |||
| Working Capital | 88.44 M | |||
| Net Asset | 107.44 M |
About Reneo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reneo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reneo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reneo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |